JP2022517461A - Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 - Google Patents

Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 Download PDF

Info

Publication number
JP2022517461A
JP2022517461A JP2021512883A JP2021512883A JP2022517461A JP 2022517461 A JP2022517461 A JP 2022517461A JP 2021512883 A JP2021512883 A JP 2021512883A JP 2021512883 A JP2021512883 A JP 2021512883A JP 2022517461 A JP2022517461 A JP 2022517461A
Authority
JP
Japan
Prior art keywords
csf
antibody
hgm
region
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517461A5 (enExample
Inventor
デュラント、キャメロン
チャペル、デール
Original Assignee
ヒューマニゲン インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/149,346 external-priority patent/US10870703B2/en
Priority claimed from US16/204,220 external-priority patent/US10899831B2/en
Priority claimed from US16/248,762 external-priority patent/US10927168B2/en
Priority claimed from US16/283,694 external-priority patent/US11130805B2/en
Application filed by ヒューマニゲン インコーポレイティッド filed Critical ヒューマニゲン インコーポレイティッド
Publication of JP2022517461A publication Critical patent/JP2022517461A/ja
Publication of JP2022517461A5 publication Critical patent/JP2022517461A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021512883A 2018-09-10 2019-09-10 Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 Pending JP2022517461A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862729043P 2018-09-10 2018-09-10
US62/729,043 2018-09-10
US16/149,346 US10870703B2 (en) 2017-10-02 2018-10-02 Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
USPCT/US2018/053933 2018-10-02
US16/149,346 2018-10-02
PCT/US2018/053933 WO2019070680A2 (en) 2017-10-02 2018-10-02 METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING GM-CSF ANTAGONIST
US16/204,220 US10899831B2 (en) 2017-10-02 2018-11-29 Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US16/204,220 2018-11-29
US16/248,762 2019-01-15
US16/248,762 US10927168B2 (en) 2017-10-02 2019-01-15 Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US16/283,694 US11130805B2 (en) 2017-10-02 2019-02-22 Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US16/283,694 2019-02-22
PCT/US2019/050494 WO2020055932A2 (en) 2018-09-10 2019-09-10 Methods of treating immunotherapy-related toxicity using a gm-csf antagonist

Publications (2)

Publication Number Publication Date
JP2022517461A true JP2022517461A (ja) 2022-03-09
JP2022517461A5 JP2022517461A5 (enExample) 2022-09-21

Family

ID=69778357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512883A Pending JP2022517461A (ja) 2018-09-10 2019-09-10 Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法

Country Status (11)

Country Link
EP (1) EP3849572A4 (enExample)
JP (1) JP2022517461A (enExample)
KR (1) KR20210075090A (enExample)
CN (1) CN113164520A (enExample)
AU (1) AU2019340662A1 (enExample)
BR (1) BR112021004489A2 (enExample)
CA (1) CA3111804A1 (enExample)
IL (1) IL281243A (enExample)
MX (1) MX2021002856A (enExample)
SG (1) SG11202102317PA (enExample)
WO (1) WO2020055932A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4314037A4 (en) * 2018-10-31 2025-06-04 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
US20220331425A1 (en) * 2019-06-03 2022-10-20 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
WO2021204649A1 (en) * 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN113402620B (zh) * 2021-07-30 2021-12-10 中山大学 细胞因子联合嵌合抗原受体的融合蛋白及其应用
CN116887856A (zh) * 2022-01-20 2023-10-13 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用
CN114606237B (zh) * 2022-05-11 2025-10-28 上海优替济生生物医药有限公司 Gm-csf抑制剂及其用途
CN119144563B (zh) * 2023-11-24 2025-11-25 成都赛恩吉诺生物科技有限公司 表达gm-csf截短功能区片段的免疫工程细胞及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518886A (ja) * 2008-04-28 2011-06-30 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
JP2020536118A (ja) * 2017-10-02 2020-12-10 ヒューマニジェン，インコーポレイテッド Ｇｍ−ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
HRP20230297T1 (hr) * 2012-07-13 2023-05-12 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
WO2018093591A1 (en) * 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
US10899831B2 (en) * 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
JP7411578B2 (ja) * 2018-06-01 2024-01-11 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 癌を治療するための物質及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518886A (ja) * 2008-04-28 2011-06-30 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
JP2020536118A (ja) * 2017-10-02 2020-12-10 ヒューマニジェン，インコーポレイテッド Ｇｍ−ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法

Also Published As

Publication number Publication date
CN113164520A (zh) 2021-07-23
WO2020055932A2 (en) 2020-03-19
WO2020055932A9 (en) 2020-07-09
MX2021002856A (es) 2021-05-28
SG11202102317PA (en) 2021-04-29
WO2020055932A3 (en) 2020-05-22
BR112021004489A2 (pt) 2021-07-20
KR20210075090A (ko) 2021-06-22
EP3849572A4 (en) 2022-07-13
IL281243A (en) 2021-04-29
AU2019340662A1 (en) 2021-05-06
EP3849572A2 (en) 2021-07-21
CA3111804A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
JP7320498B2 (ja) Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
JP6847037B2 (ja) 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
JP2022517461A (ja) Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
JP6755866B2 (ja) Ｃｄ７３特異的結合分子及びその使用
CN110066338B (zh) 作为T细胞衔接器的双特异性IgG抗体
US10899831B2 (en) Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
JP2020517302A (ja) Ｃｄ１９に対するヒト化抗原結合ドメイン及び使用方法
CN116425876A (zh) Bcma结合分子及其使用方法
KR20220007584A (ko) 항-clec2d 항체 및 이의 사용 방법
US20210230262A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
CA3172120A1 (en) Chimeric antigen receptor specific for human cd45rc and uses thereof
US20210322547A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
US20220025034A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
KR20250025354A (ko) 항-ilt3 항체 및 이의 용도
US20210290677A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
EP4506368A1 (en) Bispecific antibody to human tim-3 and human cd39, and applications thereof
CN114616245B (zh) 一种抗cd38的抗体及其用途
US20240109973A1 (en) Cd40 binding molecules and uses thereof
TW202308688A (zh) 以gm-csf拮抗劑治療免疫療法相關毒性之方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240305